Leadership - InSphero

InSphero’s leadership team combines many years’ scientific and commercial experience in 3D microtissue engineering, cell based assays, laboratory automation, and industry-scale production and quality assurance. It is complemented by the strategic management expertise of our Board of Directors and Strategic Advisory Board members.

Management Team

Jan Lichtenberg, PhD
Jan Lichtenberg, PhD
Chief Executive Officer, Co-Founder
 
Patrick Guye, PhD
Patrick Guye, PhD
Chief Scientific Officer
 
Frank Junker, PhD, MBA
Frank Junker, PhD, MBA
Chief Business Officer
 
Wolfgang Moritz, PhD
Wolfgang Moritz, PhD
Head of External Collaborations & IP
 
Marion Bavand, PhD, MBA
Marion Bavand, PhD, MBA
Head of Quality Assurance 
 
Katrin Roduner, PhD
Katrin Roduner, PhD
Head of Human Resources
 
David Fluri, PhD
David Fluri, PhD
Head of Operations
 
Tom Bishop, MS, MBA
Tom Bishop, MS, MBA
Vice President, Head of Business Development, NA
 
Martin Birk, MSc, MS (FP&A)
Martin Birk, MSc, MS (FP&A)
Head of Finance & Controlling
 
Eva Thoma, PhD
Eva Thoma, PhD
Head of Liver Solutions Group
 

Dr. Jürg Gysi, President of the Board, Switzerland

Former CEO, Promega AG Switzerland. Molecular Biologist with more than 30 years of experience in sales, marketing and management in the biotech industry in Switzerland, Germany and the US.

Dr. Jan Lichtenberg, Chief Executive Officer InSphero AG, Member of the InSphero Management Team

Co-founder of InSphero, former Head of R&D and Product Management in medical-device company Hocoma AG and Uwatec AG. Entrepreneur of the Year Switzerland in 2013 and ETH Zurich, University of Neuchâtel, EPF Lausanne and University of Bremen alumni. Founder and former CEO of Advanced Micromachining Tools GmbH.

Thomas Pfisterer, Wild Group Management AG

Heads the Direct Investments activities of the WILD Family Office since beginning of 2015. He joined the Family Office following the sale of WILD Flavors GmbH, one of the world’s leading suppliers of natural ingredients to the food and beverage industry, which he served as Head of Strategic Development directing the company’s global M&A activities since October 2011. Previously, Mr. Pfisterer worked in the investment banking division of Morgan Stanley Bank AG in Frankfurt focusing on M&A and capital market transactions for German healthcare clients. Mr. Pfisterer holds a Master in Finance (MPhil) from Cambridge University, as well as a Bachelor in Economics (B.A. HSG) and a Bachelor in Business Administration (B.A. HSG) both from University of St. Gallen.

Beat Schillig, Founder and President IFJ Institute for Young Entrepreneurs

Serial Entrepreneur and Business Angel.

Dr. Thomas Rinderknecht, Senior Partner at Badertscher Rechtsanwälte

Has served on the board of directors of several biotech, pharma and medtech companies, including Basilea, Speedel AG, Basel, Glycart Biotechnology AG and Ganymed Pharmaceuticals AG. Ph.D. in law from the University of Zurich, admitted to the Bar in Zurich.

Anna Evodokimova, VC Investment Director at Millhouse LLC

Served as the Deputy Head of Corporate Finance from 2006 to May 2015 at Millhouse LLC before. She is also Board member at Cleveland Biolabs, JSC Registrator “R.O.S.T.” “Russia Forest Product”, and “MKM-Logistics”. From 2002 to 2004, Ms. Evdokimova was the Head of Corporate Finance of the major Russian oil and gas company Slavneft. She holds a Bachelor’s degree from Moscow State Linguistic University and Master’s of Business Administration in Finance from Fordham University.

Daniel Kallay, Global Head of New Business Development, Red Bull GmbH

Served as managing director for Red Bull France, Southern Europe and Switzerland previously and is board member on a number of Swiss technology companies. He holds a Master of Economics degree from the University of St. Gallen (HSG) and an advanced leadership degree from Cambridge University.

Charles Qualls, DVM, PhD, DACVP

A toxicology expert who retired as Executive Director of Investigative Toxicology and Pathology at Amgen Inc. Before working at Amgen, Dr. Qualls served as Director of Molecular and Ultrastructural Pathology at GlaxoSmithKline. Dr. Qualls had a distinguished career over two decades in academia prior to moving into the pharmaceutical industry.

Dr. Med. Sci. Frédéric Lévy

Head of Research & Evaluation at Debiopharm International SA and Associate Professor at the Faculty of Biology and Medicine, University of Lausanne with more than 50 peer-reviewed scientific publications. Dr Med Sc, Biochemistry/Immunology and Postdoc at California Institute of Technology.